OrthoPediatrics Q3 2026 net loss narrows 50% to $5.93 million

By Public Technologies
  • OrthoPediatrics’ third-quarter 2026 net loss narrowed 50% year-over-year to $5.93 million.
  • Revenue rose 19% year-over-year to $72.7 million, driven primarily by global Trauma and Deformity and OPSB products.
  • Full market releases included the 3P Pediatric Plating Platform Hip System and PediHip Rigid Brace.
  • Full-year 2026 revenue guidance increased to $270 million–$273 million, representing growth of 14%–16% over 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OrthoPediatrics Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610271605PRIMZONEFULLFEED9854233) on October 27, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.